Cypher - The top drug-eluting stents

Stent: Cypher
2011 sales: $254 million (estimated)
Maker: Johnson & Johnson ($J&J)

Back story: What a fall for Johnson & Johnson, which basically helped create the multibillion-dollar stent business. Cypher generated $932 million in sales in 2009 and the numbers plunged after that, cratering to $643 million a year later. In 2011, Cypher produced just $253 million in sales, and J&J subsidiary Cordis, Cypher's maker, finally had enough. The company announced that it would stop making the Cypher stents by the end of 2011 and eliminate as many as 1,000 jobs in the process, done in by profound competition from companies including Abbott Laboratories ($ABT), Boston Scientific ($BSX) and Medtronic ($MDT), as they came out with easier-to-use stents, The Wall Street Journal and others reported. It was a humbling decline for J&J and Cypher, which claimed a whopping 51% of the market in 2006 before it hit just 16% in 2010. By the time 2012 numbers come out, Cypher will be history.

For more:
J&J to exit stents, cut 1,000 jobs

Cypher - The top drug-eluting stents